Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
98 hedge funds and large institutions have $900M invested in Turning Point Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 35 increasing their positions, 8 reducing their positions, and 12 closing their positions.
338% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 8
233% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 12
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
40% more funds holding
Funds holding: 70 → 98 (+28)
21% more capital invested
Capital invested by funds: $742M → $900M (+$158M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.1M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$23.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$18.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.1M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$9.14M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$3.05M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.91M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.85M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.26M |
TPTX Hedge Fund Activity: Q3 2019 in Review
98 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q3 2019, worth a combined $900M — up 21% from $742M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new TPTX positions and 12 closed out — a net gain of 28 holders — while 35 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $27.1M. The largest seller was Polar Capital, exiting entirely with an estimated $9.14M sold.
- 98 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q3 2019, up from 70 in Q2 2019.
- Funds reported $900M of Turning Point Therapeutics, Inc. Common Stock stock for Q3 2019, up 21% quarter-over-quarter.
- 40 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q3 2019 and 12 closed out, a net change of +28 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q3 2019 was Fidelity Investments, an estimated $27.1M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q3 2019 was Polar Capital, an estimated $9.14M sold.
Based on aggregated 13F filings for Q3 2019.